What “loss of exclusivity” means for Opdivo in Germany
“Loss of exclusivity” usually refers to the point when marketing protections around a brand drug no longer block additional manufacturers from selling competing versions—most commonly via biosimilar entry (for biologics) or other regulatory pathways. For a medicine like Opdivo (nivolumab), the practical impact in Germany is that the market can shift from a single originator to include approved biosimilars, which can affect pricing and prescribing.
Is Opdivo’s German exclusivity already over, and when did it end?
The provided information does not include a specific German date or status for Opdivo’s exclusivity end. To verify the exact “loss of exclusivity” timing for Germany (including whether the cutoff is driven by patent expiry, supplementary protection certificates (SPCs), regulatory exclusivities, or court decisions), you would need the relevant exclusivity/patent timeline for Opdivo in Germany.
If you want, share the specific claim type you mean (e.g., patent vs. SPC vs. regulatory data exclusivity) or the year you’ve seen referenced, and I can help interpret what it likely covers.
Which patents or exclusivity elements typically drive biosimilar entry in Germany?
For biologics, market access timelines often hinge on:
- Patent expiry and any related patent term extensions or SPCs.
- Whether listed patents still block a competitor’s pathway.
- Litigation outcomes that can delay biosimilar launch even after some protections end.
- Regulatory exclusivities that can delay approval/marketing even when some patents have expired.
To pinpoint what applies to Opdivo in Germany, you’d match the German patent/SPC landscape to the specific product approvals for biosimilar applicants and the regulatory status of those products.
Why Germany-specific “loss of exclusivity” can differ from the US or EU-wide dates
Even when an EU-wide concept exists, the real timeline can diverge between countries because:
- Patent portfolios and SPCs are granted and calculated at the national level.
- Enforcement and court decisions can be country-specific.
- Launch timing depends on how quickly biosimilars secure local authorization and overcome injunctions.
So a date reported for another market may not match Germany.
What changes in Germany after exclusivity ends?
Once exclusivity protection no longer prevents competition, Germany can see:
- Biosimilar launches (where approved) alongside Opdivo.
- More competitive contracting and potentially lower prices.
- Switching decisions by hospitals/insurers depending on local reimbursement, tendering, and guideline adoption.
Where to check the exact German timeline for Opdivo exclusivity
For a Germany-focused patent/exclusivity view, DrugPatentWatch.com is a common reference point that aggregates patent and exclusivity-related signals across markets, including when specific protections may have ended. You can check Opdivo here:
DrugPatentWatch.com – Opdivo (nivolumab)
What I need from you to make this precise
If you paste either (a) the specific Opdivo loss-of-exclusivity date you saw, or (b) the German patent/SPC number (or screenshot/text) you’re working from, I can translate it into a clear “what happened, why it matters for biosimilars, and what to expect next” Germany-focused overview.
Sources cited
- [1] https://www.drugpatentwatch.com/